Is CalciMedica, Inc. (CALC) a Buy, Sell, or Hold?
NASDAQ : CALC
CalciMedica, Inc.
$0.7527 USD
-$0.25 (-24.73%)
- Volume
- 1.12M
- Average Volume
- 1.3M
- Market Capitalization
- $11.89M
- P/E Ratio
- -0.57
- Dividend Yield
- 0.00%
- Price Target
- $392.00
- Year High
- $7.20
- Year Low
- $0.46
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.61
Company Overview
NASDAQ
A. Rachel Leheny
Biotechnology
Healthcare
CALC
16
US
USD
Liquidity Metrics
0.00
1.61
1.61
1.54
0.00
Sales & Valuation
-$
0.00
-10.23
-0.56
-1.41
Profitability
-$1.97
-$29.56M
0.00%
0.00%
4092.98%
-227.02%
P/E Metrics
-0.57
0.21
0.21
Analyst Price Target & Rating
$392.00
$392.00
$14.00
2/5
3 Analysts
-99.81%
Financial Health Scores
-35.55
1/9
$3.24M
$8.61M
$9.71M
-$18.25M
Key Metrics (TTM)
$7.63M
0.00
-0.42
1.61
4092.98%
-674.61%
-130.20%
-134.04%
-87339 days
Company Executives
| Name | Title |
|---|---|
| Patrick Hogan | Co-Founder and Scientific Advisor |
| Michael J. Dunn | President & Chief Operating Officer |
| Stefan Feske | Co-Founder and Scientific Advisor |
| A. Rachel Leheny | Chief Executive Officer & Director |
| Anjana Rao | Co-Founder and Scientific Advisor |
| Kenneth A. Stauderman | Co-Founder & Chief Scientific Officer |
| John Dunn | General Counsel |
| Eric W. Roberts | Chief Business Officer & Vice Chairman of the Board |
| Stephen Bardin | Chief Financial Officer |
| Sudarshan Hebbar | Chief Medical Officer |
Poll Results
No votes yet today — be the first to share your view!
About CalciMedica, Inc. (NASDAQ:CALC) Stock
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury. ...
2026-07-29 07:00:00
FDA aligned on new-onset severe respiratory failure as the Phase 2b primary endpoint, with multi-organ failure and time to medically indicated discharge as key secondary endpoints FDA aligned on a strategy to evaluate elevated lactate dehydrogenase (LDH) as a potential enrichment marker for identifying patients at increased risk of new-onset severe respiratory failure LA JOLLA, Calif., July 29, 2026 /PRNewswire/ -- CalciMedica, Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases, today announced that, following a Type C Focused Meeting, the U.S. Food and Drug Administration (FDA) and the Company have aligned on Phase 2b trial endpoints and a patient population enrichment strategy for its planned registration program evaluating Auxora™ in acute pancreatitis (AP).
2026-06-24 07:01:00
Proceeds expected to support a focused pulmonary hypertension strategy, including a Phase 1b proof-of-concept study evaluating Auxora™ in PAH, with data anticipated mid-2027, and advancement of oral CRAC channel inhibitor CM5480 to IND clearance expected mid-2027 Anticipated cash runway into 2H 2027 with upfront proceeds LA JOLLA, Calif., June 24, 2026 /PRNewswire/ -- CalciMedica, Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases, today announced it has entered into a definitive securities purchase agreement with leading healthcare investors for a private placement for up to approximately $49 million in gross proceeds.
2026-06-24 07:00:00
FDA reviewed a protocol amendment and interim safety data from the KOURAGE trial evaluating Auxora in AKI patients No comments or questions were received Confirms CalciMedica's ability to continue clinical development of Auxora across indications LA JOLLA, Calif., June 24, 2026 /PRNewswire/ -- CalciMedica, Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases, today announced that the U.S. Food and Drug Administration (FDA) has reviewed a protocol amendment and interim safety data for CalciMedica's Phase 2 KOURAGE trial in patients with Stage 2 or Stage 3 acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF).
CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
2026-05-12 07:00:00
FDA feedback on the Auxora™ pivotal program in acute pancreatitis and potential future development in acute kidney injury expected in 2Q 2026 Preclinical and IND-enabling studies advancing for CM5480, an oral CRAC channel inhibitor candidate, with IND submission in pulmonary hypertension expected in 2027 LA JOLLA, Calif., May 12, 2026 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious acute and chronic inflammatory, immunologic, and cardiopulmonary diseases, today reported financial results for the first quarter ended March 31, 2026 and provided clinical and corporate updates.
Frequently Asked Questions
-
What is the current CalciMedica, Inc. (CALC) stock price?
-
CalciMedica, Inc.(NASDAQ:CALC) stock price is $0.7527 in the last trading session. During the trading session, CALC stock reached the peak price of $7.2 while $0.461 was the lowest point it dropped to. The percentage change in CALC stock occurred in the recent session was --24.73% while the dollar amount for the price change in CALC stock was -$0.25.
-
CALC's industry and sector of operation?
-
The NASDAQ listed CALC is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CALC?
-
Patrick Hogan | Co-Founder and Scientific Advisor
Michael J. Dunn | President & Chief Operating Officer
Stefan Feske | Co-Founder and Scientific Advisor
A. Rachel Leheny | Chief Executive Officer & Director
Anjana Rao | Co-Founder and Scientific Advisor -
How many employees does CALC have?
-
Number of CALC employees currently stands at 16. CALC operates from 505 Coast Boulevard South, La Jolla, CA 92037, US.
-
Link for CALC official website?
-
Official Website of CALC is: https://www.calcimedica.com
-
How do I contact CALC?
-
CALC could be contacted at phone #858-952-5500 and can also be accessed through its website. CALC operates from 505 Coast Boulevard South, La Jolla, CA 92037, US.
-
How many shares of CALC are traded daily?
-
The average number of CALC shares traded daily for last 3 months was 1.3M.
-
What is the market cap of CALC currently?
-
The market value of CALC currently stands at $11.89M with its latest stock price at $0.7527